John M. Kane, MD

JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
John M. Kane, Marko A. Mychaskiw, Sangtaeck Lim, et al
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
René S. Kahn, John M. Kane, Christoph U. Correll, et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
Jose M. Rubio, Marko A. Mychaskiw, Sangtaeck Lim, et al
JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
Richard Jackson, Matthew N. Brams, Noelle E. Carlozzi, et al
JCP
Reasons for Switching Antipsychotic Treatments
Original Research

September 5, 2022

Based on prescription records and prescriber notes, almost half of antipsychotic switches were due to side effects, and women were especially likely to be switched due to intolerability or...
Daniel Guinart, Kaksha Varma, Yarden Segal, et al
JCP
ASCP Corner

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.
Jose M. Rubio, John M. Kane
JCP
Academic Highlights

May 4, 2021

What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical...
Philip D. Harvey, John M. Kane
JCP
Educational Activity

March 23, 2021

Patients may be more willing to accept some adverse effects than others. Dr Kane offers advice on addressing side effects that prevent patients from maintaining their medication adherence.
John M. Kane
JCP
Review Article

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
Daniel Guinart, Fuminari Misawa, Jose M. Rubio, et al
JCP
Letter to the Editor

June 16, 2020

Drs Kane and Correll reply to the letter "Depression as a Factor in Nonadherence in Schizophrenia" by Hirakawa and Ishii.
John M. Kane, Christoph U. Correll
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
Georgios Schoretsanitis, John M. Kane, Christoph U. Correll, et al
JCP
Academic Highlights

September 17, 2019

Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to...
John M. Kane, Christoph U. Correll

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe